These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 27559615)
1. Synthesis and Biological Evaluation of N-((1-(4-(Sulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide Inhibitors of Glycine Transporter-1. Cioffi CL; Liu S; Wolf MA; Guzzo PR; Sadalapure K; Parthasarathy V; Loong DT; Maeng JH; Carulli E; Fang X; Karunakaran K; Matta L; Choo SH; Panduga S; Buckle RN; Davis RN; Sakwa SA; Gupta P; Sargent BJ; Moore NA; Luche MM; Carr GJ; Khmelnitsky YL; Ismail J; Chung M; Bai M; Leong WY; Sachdev N; Swaminathan S; Mhyre AJ J Med Chem; 2016 Sep; 59(18):8473-94. PubMed ID: 27559615 [TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and SAR of N-((1-(4-(propylsulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide inhibitors of glycine transporter-1. Cioffi CL; Wolf MA; Guzzo PR; Sadalapure K; Parthasarathy V; Dethe D; Maeng JH; Carulli E; Loong DT; Fang X; Hu M; Gupta P; Chung M; Bai M; Moore N; Luche M; Khmelnitsky Y; Love PL; Watson MA; Mhyre AJ; Liu S Bioorg Med Chem Lett; 2013 Mar; 23(5):1257-61. PubMed ID: 23380375 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and SAR of GlyT1 inhibitors derived from a series of N-((4-(morpholine-4-carbonyl)-1-(propylsulfonyl)piperidin-4-yl)methyl)benzamides. Zhao Z; O'Brien JA; Lemaire W; Williams DL; Jacobson MA; Sur C; Pettibone DJ; Tiller PR; Smith S; Hartman GD; Wolkenberg SE; Lindsley CW Bioorg Med Chem Lett; 2006 Dec; 16(23):5968-72. PubMed ID: 16987662 [TBL] [Abstract][Full Text] [Related]
4. The discovery of potent glycine transporter type-2 inhibitors: design and synthesis of phenoxymethylbenzamide derivatives. Takahashi E; Arai T; Akahira M; Nakajima M; Nishimura K; Omori Y; Kumagai H; Suzuki T; Hayashi R Bioorg Med Chem Lett; 2014 Sep; 24(18):4603-4606. PubMed ID: 25176190 [TBL] [Abstract][Full Text] [Related]
5. A novel radioligand for glycine transporter 1: characterization and use in autoradiographic and in vivo brain occupancy studies. Zeng Z; O'Brien JA; Lemaire W; O'Malley SS; Miller PJ; Zhao Z; Wallace MA; Raab C; Lindsley CW; Sur C; Williams DL Nucl Med Biol; 2008 Apr; 35(3):315-25. PubMed ID: 18355687 [TBL] [Abstract][Full Text] [Related]
6. Discovery of N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamides as novel, selective and potent GlyT1 inhibitors. Zhao Z; Leister WH; O'Brien JA; Lemaire W; Williams DL; Jacobson MA; Sur C; Kinney GG; Pettibone DJ; Tiller PR; Smith S; Hartman GD; Lindsley CW; Wolkenberg SE Bioorg Med Chem Lett; 2009 Mar; 19(5):1488-91. PubMed ID: 19179073 [TBL] [Abstract][Full Text] [Related]
7. 2-Chloro-N-[(S)-phenyl [(2S)-piperidin-2-yl] methyl]-3-trifluoromethyl benzamide, monohydrochloride, an inhibitor of the glycine transporter type 1, increases evoked-dopamine release in the rat nucleus accumbens in vivo via an enhanced glutamatergic neurotransmission. Leonetti M; Desvignes C; Bougault I; Souilhac J; Oury-Donat F; Steinberg R Neuroscience; 2006; 137(2):555-64. PubMed ID: 16289893 [TBL] [Abstract][Full Text] [Related]
8. The synthesis and SAR of 2-arylsulfanyl-phenyl piperazinyl acetic acids as glyT-1 inhibitors. Smith G; Ruhland T; Mikkelsen G; Andersen K; Christoffersen CT; Alifrangis LH; Mørk A; Wren SP; Harris N; Wyman BM; Brandt G Bioorg Med Chem Lett; 2004 Aug; 14(15):4027-30. PubMed ID: 15225720 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and in vivo efficacy of glycine transporter-1 (GlyT1) inhibitors derived from a series of [4-phenyl-1-(propylsulfonyl)piperidin-4-yl]methyl benzamides. Lindsley CW; Zhao Z; Leister WH; O'Brien J; Lemaire W; Williams DL; Chen TB; Chang RS; Burno M; Jacobson MA; Sur C; Kinney GG; Pettibone DJ; Tiller PR; Smith S; Tsou NN; Duggan ME; Conn PJ; Hartman GD ChemMedChem; 2006 Aug; 1(8):807-11. PubMed ID: 16902933 [No Abstract] [Full Text] [Related]
10. Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. Pinard E; Alanine A; Alberati D; Bender M; Borroni E; Bourdeaux P; Brom V; Burner S; Fischer H; Hainzl D; Halm R; Hauser N; Jolidon S; Lengyel J; Marty HP; Meyer T; Moreau JL; Mory R; Narquizian R; Nettekoven M; Norcross RD; Puellmann B; Schmid P; Schmitt S; Stalder H; Wermuth R; Wettstein JG; Zimmerli D J Med Chem; 2010 Jun; 53(12):4603-14. PubMed ID: 20491477 [TBL] [Abstract][Full Text] [Related]
12. Inhibitors of GlyT1 affect glycine transport via discrete binding sites. Mezler M; Hornberger W; Mueller R; Schmidt M; Amberg W; Braje W; Ochse M; Schoemaker H; Behl B Mol Pharmacol; 2008 Dec; 74(6):1705-15. PubMed ID: 18815213 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and characterization of [¹²⁵I]2-iodo N-[(S)-{(S)-1-methylpiperidin-2-yl}(phenyl)methyl]3-trifluoromethyl-benzamide as novel imaging probe for glycine transporter 1. Fuchigami T; Haratake M; Magata Y; Haradahira T; Nakayama M Bioorg Med Chem; 2011 Nov; 19(21):6245-53. PubMed ID: 21975065 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and evaluation of N-(4-(4-phenyl piperazin-1-yl)butyl)-4-(thiophen-3-yl)benzamides as selective dopamine D Chen PJ; Taylor M; Griffin SA; Amani A; Hayatshahi H; Korzekwa K; Ye M; Mach RH; Liu J; Luedtke RR; Gordon JC; Blass BE Bioorg Med Chem Lett; 2019 Sep; 29(18):2690-2694. PubMed ID: 31387791 [TBL] [Abstract][Full Text] [Related]
16. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Depoortère R; Dargazanli G; Estenne-Bouhtou G; Coste A; Lanneau C; Desvignes C; Poncelet M; Heaulme M; Santucci V; Decobert M; Cudennec A; Voltz C; Boulay D; Terranova JP; Stemmelin J; Roger P; Marabout B; Sevrin M; Vigé X; Biton B; Steinberg R; Françon D; Alonso R; Avenet P; Oury-Donat F; Perrault G; Griebel G; George P; Soubrié P; Scatton B Neuropsychopharmacology; 2005 Nov; 30(11):1963-85. PubMed ID: 15956994 [TBL] [Abstract][Full Text] [Related]
17. Acylglycinamides as inhibitors of glycine transporter type 1. Blunt R; Porter R; Johns A; Nash D; Puckey G; Wyman P; Herdon H; Teague S; Hadden V; Fontana S; Gordon L Bioorg Med Chem Lett; 2011 Oct; 21(20):6176-9. PubMed ID: 21889344 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex. Konradsson A; Marcus MM; Hertel P; Svensson TH; Jardemark KE Synapse; 2006 Aug; 60(2):102-8. PubMed ID: 16715496 [TBL] [Abstract][Full Text] [Related]
19. The first potent and selective inhibitors of the glycine transporter type 2. Caulfield WL; Collie IT; Dickins RS; Epemolu O; McGuire R; Hill DR; McVey G; Morphy JR; Rankovic Z; Sundaram H J Med Chem; 2001 Aug; 44(17):2679-82. PubMed ID: 11495577 [No Abstract] [Full Text] [Related]
20. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]